Compare Citius Pharmaceuticals Inc (CTXR) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Ross Stores, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Ross Stores, Inc. trades at $221.08 (market cap $71.94B). The key difference: Ross Stores, Inc. is far larger — about 5281.9× Citius Pharmaceuticals Inc's market cap, and Ross Stores, Inc. pays a 0.79% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Ross Stores, Inc. for 48 Days on average.
| CTXR | ROST | |
|---|---|---|
Market Cap | $13.62M | $71.94B |
Volume | 132,438 | 2,002,519 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $255.23 |
52-Week Low | $0.48 | $147.71 |
Typical Hold Time | 16 Days | 48 Days |
Enterprise Value | $3.79M | $72.39B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Ross Stores (ROST) trades at $225.53, up 0.59% with strong fundamental performance including three consecutive earnings beats and robust profitability metrics. The stock shows bearish technical signals despite positive analyst sentiment, with 64% buy ratings and a $274.14 consensus price target representing 22% upside potential. Recent news highlights store expansion initiatives and strong closeout supply positioning the company to capture value-conscious consumer demand.
ROST presents compelling investment potential with strong earnings momentum and expanding profit margins, though technical weakness and competitive pressures warrant caution. The company's value-focused strategy and operational discipline support continued growth, while elevated valuation multiples and market volatility pose near-term risks for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
